Studies have showed that MSCs can promote tumour growth by migrating to the developing intrahepatic cholangiocarcinoma through SDF‐1α/CXCR4 signalling pathway 35, and MMP2 molecular factor in human medulloblastoma 36, in which subsequently may lead to the effects of angiogenesis via VEGF, MCP‐1 and HIF‐1 signalling pathways. The gene discussed is CCL2; the disease is cholangiocarcinoma.